PLCE

Introductory Note This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 16, 2024, as amended and supplemented by Amendments No. 1 through No. 9 to Schedule 13D filed by the Reporting Persons with the SEC on various dates between March 4, 2024 and July 7, 2026 (collectively the "Initial 13D", and the Initial 13D as amended and supplemented by this Amendment No. 10, the "Schedule 13D") relating to the common shares, par value $0.10 per share (the "Common Shares") of The Children's Place, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used in this Amendment No. 10 but not otherwise defined have the respective meanings ascribed to them in the Initial 13D. Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs to the end thereof: In Amendment No. 9, the Reporting Persons reported that Mithaq had granted stock awards to Mr. Seemab in the form of Restricted Stock in an aggregate amount of 500,000 Common Shares. At that time, Mithaq and Mr. Seemab had reached an agreement in principle concerning the stock awards. A definitive agreement concerning such awards was entered into between Mithaq and Mr. Seemab on August 11, 2026, which has been formalized as the grant date. Pursuant to the agreement, the 500,000 shares will be transferred to Mr. Seemab, who will have sole voting power over such shares and the right to receive any dividends paid on such shares. Other than the grant date, the terms of the award remain unchanged from the information in Amendment No. 9, which had reported the grant date of July 11, 2026. The vesting schedule remains the same: (i) first one-third, when the Issuer's market capitalization reaches $265 million; (ii) second one-third, when the Issuer's market capitalization reaches $400 million; and (iii) the last one-third, when the Issuer's market capitalization reaches $600 million. Unless an extension is granted by Mithaq, any unvested Common Shares will expire on the 5th anniversary of the grant date (i.e., August 11, 2031) and any unvested Common Shares will revert to Mithaq. Unless the shares vest, Mr. Seemab may not transfer the shares. Mr. Seemab will have sole dispositive power over any vested shares. The foregoing description of the restricted stock award to Mr. Seemab is qualified in its entirety by reference to the Restricted Stock Transfer Agreement dated August 11, 2026 between Mithaq and Mr. Seemab, a copy of which is filed as Exhibit 10.1 to this Amendment No. 10 and which is incorporated herein by reference.

Introductory Note This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 16, 2024, as amended and supplemented by Amendments No. 1 through No. 9 to Schedule 13D filed by the Reporting Persons with the SEC on various dates between March 4, 2024 and July 7, 2026 (collectively the "Initial 13D", and the Initial 13D as amended and supplemented by this Amendment No. 10, the "Schedule 13D") relating to the common shares, par value $0.10 per share (the "Common Shares") of The Children's Place, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used in this Amendment No. 10 but not otherwise defined have the respective meanings ascribed to them in the Initial 13D. Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs to the end thereof: In Amendment No. 9, the Reporting Persons reported that Mithaq had granted stock awards to Mr. Seemab in the form of Restricted Stock in an aggregate amount of 500,000 Common Shares. At that time, Mithaq and Mr. Seemab had reached an agreement in principle concerning the stock awards. A definitive agreement concerning such awards was entered into between Mithaq and Mr. Seemab on August 11, 2026, which has been formalized as the grant date. Pursuant to the agreement, the 500,000 shares will be transferred to Mr. Seemab, who will have sole voting power over such shares and the right to receive any dividends paid on such shares. Other than the grant date, the terms of the award remain unchanged from the information in Amendment No. 9, which had reported the grant date of July 11, 2026. The vesting schedule remains the same: (i) first one-third, when the Issuer's market capitalization reaches $265 million; (ii) second one-third, when the Issuer's market capitalization reaches $400 million; and (iii) the last one-third, when the Issuer's market capitalization reaches $600 million. Unless an extension is granted by Mithaq, any unvested Common Shares will expire on the 5th anniversary of the grant date (i.e., August 11, 2031) and any unvested Common Shares will revert to Mithaq. Unless the shares vest, Mr. Seemab may not transfer the shares. Mr. Seemab will have sole dispositive power over any vested shares. The foregoing description of the restricted stock award to Mr. Seemab is qualified in its entirety by reference to the Restricted Stock Transfer Agreement dated August 11, 2026 between Mithaq and Mr. Seemab, a copy of which is filed as Exhibit 10.1 to this Amendment No. 10 and which is incorporated herein by reference.

Introductory Note This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 16, 2024, as amended and supplemented by Amendments No. 1 through No. 9 to Schedule 13D filed by the Reporting Persons with the SEC on various dates between March 4, 2024 and July 7, 2026 (collectively the "Initial 13D", and the Initial 13D as amended and supplemented by this Amendment No. 10, the "Schedule 13D") relating to the common shares, par value $0.10 per share (the "Common Shares") of The Children's Place, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used in this Amendment No. 10 but not otherwise defined have the respective meanings ascribed to them in the Initial 13D. Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs to the end thereof: In Amendment No. 9, the Reporting Persons reported that Mithaq had granted stock awards to Mr. Seemab in the form of Restricted Stock in an aggregate amount of 500,000 Common Shares. At that time, Mithaq and Mr. Seemab had reached an agreement in principle concerning the stock awards. A definitive agreement concerning such awards was entered into between Mithaq and Mr. Seemab on August 11, 2026, which has been formalized as the grant date. Pursuant to the agreement, the 500,000 shares will be transferred to Mr. Seemab, who will have sole voting power over such shares and the right to receive any dividends paid on such shares. Other than the grant date, the terms of the award remain unchanged from the information in Amendment No. 9, which had reported the grant date of July 11, 2026. The vesting schedule remains the same: (i) first one-third, when the Issuer's market capitalization reaches $265 million; (ii) second one-third, when the Issuer's market capitalization reaches $400 million; and (iii) the last one-third, when the Issuer's market capitalization reaches $600 million. Unless an extension is granted by Mithaq, any unvested Common Shares will expire on the 5th anniversary of the grant date (i.e., August 11, 2031) and any unvested Common Shares will revert to Mithaq. Unless the shares vest, Mr. Seemab may not transfer the shares. Mr. Seemab will have sole dispositive power over any vested shares. The foregoing description of the restricted stock award to Mr. Seemab is qualified in its entirety by reference to the Restricted Stock Transfer Agreement dated August 11, 2026 between Mithaq and Mr. Seemab, a copy of which is filed as Exhibit 10.1 to this Amendment No. 10 and which is incorporated herein by reference.

Introductory Note This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 16, 2024, as amended and supplemented by Amendments No. 1 through No. 9 to Schedule 13D filed by the Reporting Persons with the SEC on various dates between March 4, 2024 and July 7, 2026 (collectively the "Initial 13D", and the Initial 13D as amended and supplemented by this Amendment No. 10, the "Schedule 13D") relating to the common shares, par value $0.10 per share (the "Common Shares") of The Children's Place, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used in this Amendment No. 10 but not otherwise defined have the respective meanings ascribed to them in the Initial 13D. Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs to the end thereof: In Amendment No. 9, the Reporting Persons reported that Mithaq had granted stock awards to Mr. Seemab in the form of Restricted Stock in an aggregate amount of 500,000 Common Shares. At that time, Mithaq and Mr. Seemab had reached an agreement in principle concerning the stock awards. A definitive agreement concerning such awards was entered into between Mithaq and Mr. Seemab on August 11, 2026, which has been formalized as the grant date. Pursuant to the agreement, the 500,000 shares will be transferred to Mr. Seemab, who will have sole voting power over such shares and the right to receive any dividends paid on such shares. Other than the grant date, the terms of the award remain unchanged from the information in Amendment No. 9, which had reported the grant date of July 11, 2026. The vesting schedule remains the same: (i) first one-third, when the Issuer's market capitalization reaches $265 million; (ii) second one-third, when the Issuer's market capitalization reaches $400 million; and (iii) the last one-third, when the Issuer's market capitalization reaches $600 million. Unless an extension is granted by Mithaq, any unvested Common Shares will expire on the 5th anniversary of the grant date (i.e., August 11, 2031) and any unvested Common Shares will revert to Mithaq. Unless the shares vest, Mr. Seemab may not transfer the shares. Mr. Seemab will have sole dispositive power over any vested shares. The foregoing description of the restricted stock award to Mr. Seemab is qualified in its entirety by reference to the Restricted Stock Transfer Agreement dated August 11, 2026 between Mithaq and Mr. Seemab, a copy of which is filed as Exhibit 10.1 to this Amendment No. 10 and which is incorporated herein by reference.

Introductory Note This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 16, 2024, as amended and supplemented by Amendments No. 1 through No. 9 to Schedule 13D filed by the Reporting Persons with the SEC on various dates between March 4, 2024 and July 7, 2026 (collectively the "Initial 13D", and the Initial 13D as amended and supplemented by this Amendment No. 10, the "Schedule 13D") relating to the common shares, par value $0.10 per share (the "Common Shares") of The Children's Place, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used in this Amendment No. 10 but not otherwise defined have the respective meanings ascribed to them in the Initial 13D. Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs to the end thereof: In Amendment No. 9, the Reporting Persons reported that Mithaq had granted stock awards to Mr. Seemab in the form of Restricted Stock in an aggregate amount of 500,000 Common Shares. At that time, Mithaq and Mr. Seemab had reached an agreement in principle concerning the stock awards. A definitive agreement concerning such awards was entered into between Mithaq and Mr. Seemab on August 11, 2026, which has been formalized as the grant date. Pursuant to the agreement, the 500,000 shares will be transferred to Mr. Seemab, who will have sole voting power over such shares and the right to receive any dividends paid on such shares. Other than the grant date, the terms of the award remain unchanged from the information in Amendment No. 9, which had reported the grant date of July 11, 2026. The vesting schedule remains the same: (i) first one-third, when the Issuer's market capitalization reaches $265 million; (ii) second one-third, when the Issuer's market capitalization reaches $400 million; and (iii) the last one-third, when the Issuer's market capitalization reaches $600 million. Unless an extension is granted by Mithaq, any unvested Common Shares will expire on the 5th anniversary of the grant date (i.e., August 11, 2031) and any unvested Common Shares will revert to Mithaq. Unless the shares vest, Mr. Seemab may not transfer the shares. Mr. Seemab will have sole dispositive power over any vested shares. The foregoing description of the restricted stock award to Mr. Seemab is qualified in its entirety by reference to the Restricted Stock Transfer Agreement dated August 11, 2026 between Mithaq and Mr. Seemab, a copy of which is filed as Exhibit 10.1 to this Amendment No. 10 and which is incorporated herein by reference.

Introductory Note This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed by the Reporting Persons with the SEC on February 16, 2024, as amended and supplemented by Amendments No. 1 through No. 9 to Schedule 13D filed by the Reporting Persons with the SEC on various dates between March 4, 2024 and July 7, 2026 (collectively the "Initial 13D", and the Initial 13D as amended and supplemented by this Amendment No. 10, the "Schedule 13D") relating to the common shares, par value $0.10 per share (the "Common Shares") of The Children's Place, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used in this Amendment No. 10 but not otherwise defined have the respective meanings ascribed to them in the Initial 13D. Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs to the end thereof: In Amendment No. 9, the Reporting Persons reported that Mithaq had granted stock awards to Mr. Seemab in the form of Restricted Stock in an aggregate amount of 500,000 Common Shares. At that time, Mithaq and Mr. Seemab had reached an agreement in principle concerning the stock awards. A definitive agreement concerning such awards was entered into between Mithaq and Mr. Seemab on August 11, 2026, which has been formalized as the grant date. Pursuant to the agreement, the 500,000 shares will be transferred to Mr. Seemab, who will have sole voting power over such shares and the right to receive any dividends paid on such shares. Other than the grant date, the terms of the award remain unchanged from the information in Amendment No. 9, which had reported the grant date of July 11, 2026. The vesting schedule remains the same: (i) first one-third, when the Issuer's market capitalization reaches $265 million; (ii) second one-third, when the Issuer's market capitalization reaches $400 million; and (iii) the last one-third, when the Issuer's market capitalization reaches $600 million. Unless an extension is granted by Mithaq, any unvested Common Shares will expire on the 5th anniversary of the grant date (i.e., August 11, 2031) and any unvested Common Shares will revert to Mithaq. Unless the shares vest, Mr. Seemab may not transfer the shares. Mr. Seemab will have sole dispositive power over any vested shares. The foregoing description of the restricted stock award to Mr. Seemab is qualified in its entirety by reference to the Restricted Stock Transfer Agreement dated August 11, 2026 between Mithaq and Mr. Seemab, a copy of which is filed as Exhibit 10.1 to this Amendment No. 10 and which is incorporated herein by reference.